Home Infusion Therapy Market Size, sha

The Home Infusion Therapy Market is gaining traction worldwide as patients increasingly prefer cost-effective and convenient treatment at home over long hospital stays. Valued at USD 39.05 billion in 2024, the market is projected to grow from USD 42.18 billion in 2025 to USD 78.06 billion by 2033, registering a CAGR of 8% during the forecast period.

👉 Download Sample Report

Home infusion therapy allows patients to receive medications using needles or catheters in the comfort of their homes. This includes treatment for infections, pain management, nutrition, immune-related conditions, and chronic diseases like heart failure and rheumatoid arthritis. With rising healthcare costs and increasing geriatric populations, the adoption of home infusion therapy is accelerating across the globe.

• Increasing geriatric population: By 2034, nearly 77 million Americans will be aged 65+, growing to 94.7 million by 2060. This age group is more likely to require long-term care, fueling demand for home-based treatments.

• Rising prevalence of chronic diseases: According to WHO, chronic illnesses like cancer, diabetes, and cardiovascular conditions account for 60% of all deaths globally, projected to rise to 73% by 2030. Many of these patients benefit from infusion therapies at home.

• Cost-effectiveness and convenience: Home infusion costs around USD 150–200 per day, significantly lower than inpatient hospital stays ranging from USD 1,500–2,500 per day.

The market faces challenges due to complex reimbursement structures and cuts in Medicare funding, which may limit affordability for senior citizens and slow adoption.

Emerging markets in Asia-Pacific and Latin America present strong growth potential due to improving healthcare infrastructure, rising disposable incomes, and increasing awareness of advanced home-care solutions.

• North America dominates the global market, expected to expand at a CAGR of 7.3%, reaching USD 36,065 million by 2030. The region benefits from strong reimbursement frameworks and a high burden of chronic diseases.

• Asia-Pacific is projected to witness the fastest growth with a CAGR of 9.5%, reaching USD 9,945 million by 2030, driven by government initiatives, improving healthcare systems, and rising awareness in countries like Japan and China.

• By Type: Products, Services

• By Product: Infusion Pumps, Intravenous Sets, IV Cannulas, Needleless Connectors

• By Application: Anti-Infective, Endocrinology, Hydration Therapy, Chemotherapy, Enteral Nutrition, Parenteral Nutrition, Specialty Pharmaceuticals

• By Region: North America, Europe, Asia-Pacific, Middle East & Africa, Latin America

• Option Care Health (BrioScrip)

• CVS (Coram)

• United Health Care (BriovaRx)

• PharMerica

• Baxter

• Caesarea Medical Electronics

• CareFusion Corporation

• Terumo Corporation

• B. Braun Melsungen AG

• ICU Medical, Inc.

• Fresenius Kabi AG

• JMS Co. Ltd.

• Smiths Medical

• 2021: Smiths Medical partnered with Ivenix, Inc. to expand infusion management solutions in the U.S.

• 2021: Smiths Medical collaborated with Parkview Health to integrate PharmGuard Infusion Management System with EHR.

• 2020: B. Braun received FDA clearance for its SpaceStation MRI, enabling continuous medication delivery during MRI scans.

Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.

Contact Us:
Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website: https://straitsresearch.com/